Woodmont Investment Counsel LLC Purchases 16,987 Shares of Pfizer Inc. (NYSE:PFE)

Woodmont Investment Counsel LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 6.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 269,981 shares of the biopharmaceutical company’s stock after acquiring an additional 16,987 shares during the quarter. Woodmont Investment Counsel LLC’s holdings in Pfizer were worth $6,841,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Tallon Kerry Patrick purchased a new stake in shares of Pfizer during the 4th quarter valued at $509,000. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the last quarter. Venturi Wealth Management LLC boosted its holdings in shares of Pfizer by 23.1% in the 4th quarter. Venturi Wealth Management LLC now owns 6,181 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 1,159 shares in the last quarter. Finally, Ieq Capital LLC increased its position in shares of Pfizer by 14.3% during the 4th quarter. Ieq Capital LLC now owns 320,472 shares of the biopharmaceutical company’s stock valued at $8,502,000 after purchasing an additional 40,117 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Price Performance

Shares of PFE opened at $23.97 on Friday. The firm has a fifty day simple moving average of $23.26 and a two-hundred day simple moving average of $24.90. The firm has a market cap of $136.27 billion, a PE ratio of 17.37, a P/E/G ratio of 0.87 and a beta of 0.57. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.82 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.18%. The ex-dividend date was Friday, May 9th. Pfizer’s dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.